Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)
Aug 29, 2020
- Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab
- Seven of ten patients discontinued eculizumab and remained on LNP023 as monotherapy, retaining hemoglobin (Hb) levels with no changes in biomarkers of disease activity and with no signs or symptoms of breakthrough hemolysis
- Phase II results are promising for treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder;1,2?second Phase II study with LNP023 monotherapy in anti-C5 na?ve PNH patients ongoing?
- First-in-class LNP023 ? which potently and selectively targets factor B, part of the immune system?s alternative complement pathway3,4,5?? is also in development for several renal conditions with complement system involvement
- FDA and EMA have granted orphan drug designations to LNP023 for PNH and the rare renal disease complement 3 glomerulopathy (C3G)
# # #
Novartis Media Relations E-mail:?media.relations@novartis.comAnja von Treskow Novartis Global Media Relations +41 61 324 2279 (direct) +41 79 392 8697 (mobile) anja.von_treskow@novartis.com | Michael Billings Novartis Hematology Communications +1 862 778 8656 (direct) +1 201 400 1854 (mobile) michael.billings@novartis.com |
Eric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com | Phil McNamara Novartis Cardio-Metabolic Communications +1 862 778 0218 (direct) +1 862 274 5255 (mobile) philip.mcnamara@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 778 5052 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck | +41 61 324 7188 |